Disparities in the organisation of national healthcare systems for treatment of patients with psoriatic arthritis and axial spondyloarthritis across Europe.
Michelsen B, Østergaard M, Nissen MJ, Ciurea A, Möller B, Midtbøll Ørnbjerg L, Horák P, Glintborg B, MacDonald A, Laas K, Sokka-Isler T, Gudbjornsson B, Iannone F, Hellamand P, Kvien TK, Rodrigues AM, Codreanu C, Rotar Z, Castrejón I, Wallman JK, Pavelka K, Loft AG, Heddle M, Vorobjov S, Relas H, Gröndal G, Gremese E, van der Horst-Bruinsma I, Kristianslund EK, Santos MJ, Mogosan C, Tomsic M, Diaz-Gonzalez F, Giuseppe DD, Nielsen SW, Hetland ML.
Michelsen B, et al.
Health Policy. 2025 Jun;156:105311. doi: 10.1016/j.healthpol.2025.105311. Epub 2025 Apr 4.
Health Policy. 2025.
PMID: 40245675
Free article.
Review.
OBJECTIVES: To map and compare national healthcare set-ups for prescription, start, switch, tapering, and discontinuation of biologic/targeted synthetic disease-modifying antirheumatic drugs (DMARDs) in patients with psoriatic arthritis and axial spondyloarthritis across Europe, …
OBJECTIVES: To map and compare national healthcare set-ups for prescription, start, switch, tapering, and discontinuation of biologic/target …